Retension Pharmaceuticals (RTSN) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Asset and mechanism

• RTN-001 is a second-generation PDE5 inhibitor in development for resistant and uncontrolled hypertension and other cardiovascular diseases; its design targets central vascular tissues.

• The Modulon platform was developed to reduce binding to elastic proteins, aiming to improve drug access to the aorta, heart and central vasculature.

• The asset originated at Surface Logix and was licensed back to launch development; vardenafil was selected as the most potent first-generation PDE5 inhibitor, with tissue distribution—not potency or PK—the development focus.

Hypertension need and preclinical findings

• Hypertension affects 1.4B people worldwide and 120M U.S. adults; 80% of U.S. patients are not at goal, while treatment targets have moved toward 120 mmHg.

• Preclinical studies showed nearly an order of magnitude more free drug in the aorta and heart than reported for first-generation PDE5 inhibitors, plus dose-responsive blood-pressure lowering in hypertensive rats.

• Executives cited a study finding that a 5 mmHg blood-pressure reduction corresponded to a 10% improvement in cardiovascular events.

Clinical experience and modified release

• Across nine prior studies, 265 patients participated and 243 received RTN-001; seven studies supported a safety profile similar to first-generation PDE5 inhibitors, with no SAEs reported.

• Two short hypertension studies, with dosing for 12 or 14 days, showed clinically meaningful blood-pressure reductions in patients taking up to four background medications.

• Immediate-release data showed placebo-adjusted peak blood-pressure reductions of 10–12.5 mmHg in the first 6–8 hours, waning by 24 hours; the reported half-life was 6–8 hours.

• Modified release increased parent-drug levels at 24 hours sixfold and reduced Cmax by ~5-fold, targeting once-daily 24-hour coverage and fewer Cmax-driven adverse events.

• Prior proof-of-concept work reported equipotent central and peripheral pressure reductions, including central effects one hour after an initial dose.